Related Experiment Video

Updated: Aug 10, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Variable effects of beta-carotene therapy in a child with erythropoietic protoporphyria

Ramin Alemzadeh1, Tammy Feehan

  • 1Department of Pediatrics, University of Tennessee Medical Center, Knoxville, Tennessee, USA. ralemzad@mcw.edu

European Journal of Pediatrics
|July 9, 2004
PubMed

Insights

High-dose beta-carotene therapy offers photoprotection for erythropoietic protoporphyria (EPP), improving sun tolerance in patients. This treatment showed significant benefits for skin lesions in a pediatric case study.

Area of Science:

  • Biochemistry
  • Dermatology
  • Genetics

Background:

  • Erythropoietic protoporphyria (EPP) is a genetic disorder of heme biosynthesis.
  • Patients with EPP experience photosensitivity due to protoporphyrin accumulation.

Observation:

  • A 5-year-old female with EPP presented with recurrent facial blisters and sun-exposed skin lesions.
  • Standard sunblock and photoprotection measures provided only moderate relief.

Findings:

  • Treatment with high-dose beta-carotene (90-180 mg/day) over three months led to marked improvement in facial and forearm lesions.
  • A modest improvement was observed in lesions on the patient's hands.

Implications:

  • High-dose beta-carotene may serve as an effective photoprotective agent for EPP.
  • Further research is warranted to optimize beta-carotene dosage and assess long-term efficacy in EPP management.
Abstract

More Related Videos

Measurement of Carotenoids in Perifovea using the Macular Pigment Reflectometer09:35

Measurement of Carotenoids in Perifovea using the Macular Pigment Reflectometer

Published on: January 29, 2020

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...